Nuclear security contract from US federal entity
23 September 2021
Kromek Group plc
("Kromek" or the "Group")
Kromek receives D3S-ID 'dirty bomb' detector contract from US federal entity
Kromek (AIM: KMK), a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, announces that it has received a contract worth up to $1.6m from a US federal entity for the Group's D3S-ID wearable nuclear radiation detector that is designed to enable first responders, armed forces, border security and other CBRN experts detect radiological threats. The contract will be delivered over two years commencing immediately.
The D3S-ID is a wearable gamma neutron RIID (radioisotope identification device) that is continuously scanning to identify radioisotopes and detect neutrons in real time. The Group believes that it is one of the fastest and most accurate isotope identification devices in its class on the market. It is designed to detect radiological threats like dirty bombs, radioactive contamination, smuggling of radioactive substances and radiation at the scene of an accident or terrorist attack. Kromek's D3S platform - comprising the Group's range of D3S products - is widely deployed as a networked solution to protect cities, buildings or critical infrastructure.
Dr Arnab Basu, CEO of Kromek, said:
"We're pleased to have received this contract from a US federal entity for our D3S-ID nuclear radiation detector that provides a comprehensive but cost-effective solution for the detection of nuclear threats.
"Only last month there was an incident in France of a student building a dirty bomb with uranium oxide bought on a widely used online platform. This case highlights both the pervasiveness and accessibility of such dangers and the need for constant monitoring. Solutions such as our D3S platform, which is continuously scanning in real time, provides security authorities with an early warning system for potential threats, enabling a more effective response.
"With global defence and security spend on the rise around the world in response to volatile international relations, we expect to receive further orders for our nuclear security products, contributing to our significant anticipated revenue growth for this year and our pipeline for the years ahead."
For further information, please contact:
|
Kromek Group plc |
|
|
Arnab Basu, CEO Paul Farquhar, CFO |
+44 (0)1740 626 060 |
|
|
|
|
Cenkos Securities plc (Nominated Adviser and Broker) |
|
|
Camilla Hume/Giles Balleny (NOMAD) Julian Morse (Sales) |
+44 (0)20 7397 8900 |
|
|
|
|
Luther Pendragon (Financial PR) |
|
|
Harry Chathli/Claire Norbury |
+44 (0)20 7618 9100 |
About Kromek Group plc
Kromek Group plc is a technology group (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT") and other advanced technologies. Using its core technology platforms, Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.
The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.
The Group's business model provides a vertically integrated technology offering to customers, from radiation detector materials to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").
The Group has operations in the UK and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.
Currently, the Group has over 150 full-time employees across its global operations. Further information on Kromek Group is available at www.kromek.com and https://twitter.com/kromekgroup.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund